Cicatrix Clinical Trial
Official title:
Fractional CO2 Laser Assisted Topical Articaine Anesthesia vs. Topical EMLA Administration: a Randomized Controlled Study
The purpose of this study is to assess the efficacy of skin anesthesia using fractional laser assisted delivery of articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) compared to standard anesthesia with topical eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) prior to ablative fractional laser treatment of acne scars and traumatic scars.
Rationale: In dermatology, many minor surgical and laser procedures are carried out under
local anesthesia of the skin. Anesthesia using topical formulations is time consuming, as the
anesthetic has to be applied at least one hour before treatment, and is often only partially
effective. On the other hand infiltration anesthesia is often associated with discomfort and
is not tolerated by patients who are for example needle phobic. In the past years, Haedersdal
and colleagues have shown that the penetration of various topically applied substances,
including photosensitizers, into the skin can be enhanced and accelerated by pretreatment of
the skin with a fractional laser, creating a pattern of microscopic ablation craters.1 This
improvement in drug penetration is regardless of ablation crater depth.2 There is limited
evidence that transepidermal lidocaine absorption can be increased by fractional laser
pretreatment.3, 4 These findings might suggest that local anesthesia of the skin may be
achieved by applying an anesthetic topically on a skin surface pretreated with a fractional
laser. The investigators of the present study hypothesize that fractional laser assisted
delivery of topical anesthetics might give a faster and better anesthetic effect, than
treatment with the standard treatment of topical anesthesia.
Objective: The objective of this study is to assess the efficacy of skin anesthesia using
fractional laser assisted delivery of articaine hydrochloride 40 mg/ml and epinephrine 10
µg/ml solution (AHES) compared to standard anesthesia with topical eutectic mixture of
lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream).
Study design: Prospective, open label, randomized controlled, within subject, study.
Study population: patients >18 years, who give written informed consent, visiting the
institute for fractional carbon dioxide laser treatment for acne scars or traumatic scars.
Intervention (if applicable): In each patient, the lesional area will be divided into two
comparable regions during the visit prior to the (next) fractional laser treatment. These
regions will then be randomly allocated to either standard anesthesia with EMLA cream
(control region; region I) or ablative fractional laser (AFXL) assisted delivery of AHES
(intervention region; region II). Patients will be asked to apply EMLA cream at region I
under occlusion two hours prior to the laser treatment. Fifteen minutes before the
therapeutic laser treatment of the scars, the skin of region II will be pretreated with the
fractional carbon dioxide laser (15% density, 2.5 mJ/microbeam). Directly following
fractional laser pretreatment, AHES will be topically applied under occlusion at region II
for 15 minutes. Subsequently treatment of both regions will be performed with the same
fractional carbon dioxide laser at the settings used in routine clinical practice. Directly
after this therapeutic laser treatment, patients will be asked to indicate pain per test
region on a visual analogue scale (VAS) from 0-10 (0: no pain; 10: worst imaginable pain).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02645773 -
Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring
|
N/A | |
Completed |
NCT02672956 -
Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results
|
N/A | |
Completed |
NCT00629811 -
Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women
|
Phase 2 | |
Completed |
NCT00847795 -
Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.
|
Phase 1/Phase 2 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03213548 -
Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty
|
N/A | |
Recruiting |
NCT05377723 -
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
|
N/A | |
Active, not recruiting |
NCT01976260 -
A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars
|
N/A | |
Terminated |
NCT00432328 -
Juvista (Avotermin) in Breast Reduction Surgery Scars
|
Phase 2 | |
Completed |
NCT00594581 -
Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
|
Phase 2 | |
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 | |
Recruiting |
NCT04420442 -
Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars
|
N/A | |
Completed |
NCT02772289 -
Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 | |
Completed |
NCT00430326 -
Juvista (Avotermin) in Scars Following Varicose Vein Removal
|
Phase 2 | |
Completed |
NCT00847925 -
Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT05787171 -
Three Sutures With Different Absorption Rates for Lower Abdominal Incision
|
N/A | |
Completed |
NCT02985151 -
Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
|
N/A | |
Completed |
NCT02340325 -
FS2 Safety and Tolerability Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00432211 -
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
|
Phase 2 | |
Completed |
NCT00978302 -
Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
|
Phase 1 |